Transgene Biotek
TRABIBSE

Transgene Biotek

₹3.04-0.06 (1.94%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
3.02
Today’s high
3.04
52 week low
1.83
52 week high
5.26
Open price
3.02
Previous close
3.10
Live volume
401
Lower circuit
2.48
Upper circuit
3.72

Fundamentals

Market Cap
₹23Cr
ROE
-19.73%
P/E Ratio(TTM)
-12.36
EPS(TTM)
-0.22
P/B Ratio
2.80
Dividend Yield
0.00%
Industry P/E
58.55
Book Value
1.11
Debt to Equity
2.05
Face Value
10

Financial performance

Quarterly
Yearly
All Financials
MAR '26
Revenue (Cr)
₹0.20
+300.00%
Profit (Cr)
-₹0.46
-24.32%
-2-1012
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Revenue growthValue
1Y (TTM)+67%
3Y CAGR+52%
Profit growthValue
1Y (TTM)+54%
3Y CAGR+149%

About

Transgene Biotek Limited is a bio-pharmaceutical company dedicated to researching and developing innovative biologic molecules for therapeutic use, operating within the Indian bulk drugs sector. Its governance framework is fundamentally driven by the objective of enhancing long-term stakeholder value without compromising on crucial ethical standards or corporate social responsibilities. The company's approach to accountability involves taking firm responsibility for its promises and promoting a mindset of ownership throughout the organization. Core activities involve creating stable formulations for oral or nasal delivery, which conveniently avoids injections, and initiating studies for regulatory approval to commercialize its molecules. Through a strategic alliance with NiedlFree, Transgene expects to achieve rapid progress in the commercialization of its technologies and deliver benefits to the company. This partnership has successfully addressed formulation challenges, leading to the demonstration of exceptional bio-availability, a vital marker of technological success and effectiveness.;
CEO/MD
Dr. K. Koteswara Rao
Founded in
1990
BSE symbol
526139

Shareholding Pattern

Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Retail And Others
76.36%
Promoters
23.64%
2026
29
May
Quarterly & Annual Result
Release date
13
Feb
Quarterly Result
Release date
2025
14
Nov
Quarterly Result
Release date
7
Aug
Quarterly Result
Release date
Events calendar
View upcoming events in other stocks